Swine pseudorabies virus attenuated vaccine reprograms the kidney cancer tumor microenvironment and synergizes with PD‐1 blockade
The global incidence rate of kidney cancer (KC) has been steadily increasing over the past 30 years. With the aging global population, kidney cancer has become an escalating concern that necessitates vigilant surveillance. Nowadays, surgical intervention remains the optimal therapeutic approach for...
Saved in:
Published in | Journal of medical virology Vol. 96; no. 4; pp. e29568 - n/a |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.04.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The global incidence rate of kidney cancer (KC) has been steadily increasing over the past 30 years. With the aging global population, kidney cancer has become an escalating concern that necessitates vigilant surveillance. Nowadays, surgical intervention remains the optimal therapeutic approach for kidney cancer, while the availability of efficacious treatments for advanced tumors remains limited. Oncolytic viruses, an emerging form of immunotherapy, have demonstrated encouraging anti‐neoplastic properties and are progressively garnering public acceptance. However, research on oncolytic viruses in kidney cancer is relatively limited. Furthermore, given the high complexity and heterogeneity of kidney cancer, it is crucial to identify an optimal oncolytic virus agent that is better suited for its treatment. The present study investigates the oncolytic activity of the Pseudorabies virus live attenuated vaccine (PRV‐LAV) against KC. The findings clearly demonstrate that PRV‐LAV exhibits robust oncolytic activity targeting KC cell lines. Furthermore, the therapeutic efficacy of PRV‐LAV was confirmed in both a subcutaneous tumor‐bearing nude mouse model and a syngeneic mouse model of KC. Combined RNA‐seq analysis and flow cytometry revealed that PRV‐LAV treatment substantially enhances the infiltration of a diverse range of lymphocytes, including T cells, B cells, macrophages, and NK cells. Additionally, PRV‐LAV treatment enhances T cell activation and exerts antitumor effects. Importantly, the combination of PRV‐LAV with anti‐PD‐1 antibodies, an approved drug for KC treatment, synergistically enhances the efficacy against KC. Overall, the discovery of PRV‐LAV as an effective oncolytic virus holds significant importance for improving the treatment efficacy and survival rates of KC patients. |
---|---|
AbstractList | The global incidence rate of kidney cancer (KC) has been steadily increasing over the past 30 years. With the aging global population, kidney cancer has become an escalating concern that necessitates vigilant surveillance. Nowadays, surgical intervention remains the optimal therapeutic approach for kidney cancer, while the availability of efficacious treatments for advanced tumors remains limited. Oncolytic viruses, an emerging form of immunotherapy, have demonstrated encouraging anti‐neoplastic properties and are progressively garnering public acceptance. However, research on oncolytic viruses in kidney cancer is relatively limited. Furthermore, given the high complexity and heterogeneity of kidney cancer, it is crucial to identify an optimal oncolytic virus agent that is better suited for its treatment. The present study investigates the oncolytic activity of the Pseudorabies virus live attenuated vaccine (PRV‐LAV) against KC. The findings clearly demonstrate that PRV‐LAV exhibits robust oncolytic activity targeting KC cell lines. Furthermore, the therapeutic efficacy of PRV‐LAV was confirmed in both a subcutaneous tumor‐bearing nude mouse model and a syngeneic mouse model of KC. Combined RNA‐seq analysis and flow cytometry revealed that PRV‐LAV treatment substantially enhances the infiltration of a diverse range of lymphocytes, including T cells, B cells, macrophages, and NK cells. Additionally, PRV‐LAV treatment enhances T cell activation and exerts antitumor effects. Importantly, the combination of PRV‐LAV with anti‐PD‐1 antibodies, an approved drug for KC treatment, synergistically enhances the efficacy against KC. Overall, the discovery of PRV‐LAV as an effective oncolytic virus holds significant importance for improving the treatment efficacy and survival rates of KC patients. Abstract The global incidence rate of kidney cancer (KC) has been steadily increasing over the past 30 years. With the aging global population, kidney cancer has become an escalating concern that necessitates vigilant surveillance. Nowadays, surgical intervention remains the optimal therapeutic approach for kidney cancer, while the availability of efficacious treatments for advanced tumors remains limited. Oncolytic viruses, an emerging form of immunotherapy, have demonstrated encouraging anti‐neoplastic properties and are progressively garnering public acceptance. However, research on oncolytic viruses in kidney cancer is relatively limited. Furthermore, given the high complexity and heterogeneity of kidney cancer, it is crucial to identify an optimal oncolytic virus agent that is better suited for its treatment. The present study investigates the oncolytic activity of the Pseudorabies virus live attenuated vaccine (PRV‐LAV) against KC. The findings clearly demonstrate that PRV‐LAV exhibits robust oncolytic activity targeting KC cell lines. Furthermore, the therapeutic efficacy of PRV‐LAV was confirmed in both a subcutaneous tumor‐bearing nude mouse model and a syngeneic mouse model of KC. Combined RNA‐seq analysis and flow cytometry revealed that PRV‐LAV treatment substantially enhances the infiltration of a diverse range of lymphocytes, including T cells, B cells, macrophages, and NK cells. Additionally, PRV‐LAV treatment enhances T cell activation and exerts antitumor effects. Importantly, the combination of PRV‐LAV with anti‐PD‐1 antibodies, an approved drug for KC treatment, synergistically enhances the efficacy against KC. Overall, the discovery of PRV‐LAV as an effective oncolytic virus holds significant importance for improving the treatment efficacy and survival rates of KC patients. |
Author | Gui, Mengxuan Cao, Jiali Zeng, Yue Lin, Lina Yuan, Quan Chen, Kaiyun Xia, Ningshao He, Peiqing Fu, Rao Wu, Qian Huang, Pengfei Chen, Tian Zhang, Tianying Han, Qiangyuan Wang, Guosong Qi, Ruoyao Wu, Chongxin Chen, Yixin |
Author_xml | – sequence: 1 givenname: Mengxuan surname: Gui fullname: Gui, Mengxuan organization: Xiamen University – sequence: 2 givenname: Chongxin surname: Wu fullname: Wu, Chongxin organization: Xiamen University – sequence: 3 givenname: Ruoyao surname: Qi fullname: Qi, Ruoyao organization: Xiamen University – sequence: 4 givenname: Yue surname: Zeng fullname: Zeng, Yue organization: Xiamen University – sequence: 5 givenname: Pengfei surname: Huang fullname: Huang, Pengfei organization: Xiamen University – sequence: 6 givenname: Jiali orcidid: 0000-0002-6286-5574 surname: Cao fullname: Cao, Jiali organization: Xiamen University – sequence: 7 givenname: Tian surname: Chen fullname: Chen, Tian organization: Xiamen University – sequence: 8 givenname: Kaiyun surname: Chen fullname: Chen, Kaiyun organization: Xiamen University – sequence: 9 givenname: Lina surname: Lin fullname: Lin, Lina organization: Xiamen University – sequence: 10 givenname: Qiangyuan surname: Han fullname: Han, Qiangyuan organization: Xiamen University – sequence: 11 givenname: Peiqing surname: He fullname: He, Peiqing organization: Xiamen University – sequence: 12 givenname: Rao surname: Fu fullname: Fu, Rao organization: Xiamen University – sequence: 13 givenname: Qian surname: Wu fullname: Wu, Qian organization: Xiamen University – sequence: 14 givenname: Quan surname: Yuan fullname: Yuan, Quan organization: Xiamen University – sequence: 15 givenname: Tianying surname: Zhang fullname: Zhang, Tianying organization: Xiamen University – sequence: 16 givenname: Ningshao orcidid: 0000-0003-0179-5266 surname: Xia fullname: Xia, Ningshao organization: Xiamen University – sequence: 17 givenname: Guosong surname: Wang fullname: Wang, Guosong email: wangguosong2020@xmu.edu.cn organization: Xiamen University – sequence: 18 givenname: Yixin orcidid: 0000-0002-9591-634X surname: Chen fullname: Chen, Yixin email: yxchen2008@xmu.edu.cn organization: Xiamen University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38549430$$D View this record in MEDLINE/PubMed |
BookMark | eNp10ctu1DAYhmELFdFpYcENIEtsYJHWpzj2EpVTUSuQOGwj2_ndepo4UzuZ0bBC4ga4Rq6kbqewQGLlzaNX_vUdoL04RkDoKSVHlBB2vBzWR0zXUj1AC0q0rDRp6B5aECpkJSWt99FBzktCiNKMPUL7XNVCC04W6OfnTYiAVxnmbkzGBsh4HdKcsZkmiLOZoMNr49ytSrBK40UyQ8bTJeCr0EXYYmeig4SneRgTHoJLI8SSGOMAccImdjhvI6SL8L20N2G6xJ9e__7xi2Lbj-7KdPAYPfSmz_Dk_j1EX9---XLyvjr7-O705NVZ5bhQqvLWCtp4arX1jjXKd53kshzEBDeOWEEooao23tQKlHYN81YLKZUyDfeO80P0YtctV1zPkKd2CNlB35sI45xbThirpSasKfT5P3Q5zimW3xUlFK91o0lRL3eq3JxzAt-uUhhM2raUtLfLtGWZ9m6ZYp_dF2c7QPdX_pmigOMd2IQetv8vtR_Ov-2SN_ZPnNE |
Cites_doi | 10.3322/caac.21208 10.3322/caac.21492 10.1080/15384101.2022.2117910 10.3322/caac.21660 10.1126/scitranslmed.aau0417 10.1126/scitranslmed.aao1641 10.3389/fonc.2017.00107 10.1016/S0140-6736(08)60269-X 10.1634/theoncologist.2009-0088 10.1371/journal.ppat.1006314 10.1038/nrd4663 10.3322/caac.20132 10.1158/1078-0432.CCR-16-0143 10.1586/era.09.43 10.1007/s00125-022-05750-1 10.1146/annurev-immunol-032713-120136 10.1172/JCI98047 10.1158/2159-8290.CD-11-0098 10.1016/j.antiviral.2021.105014 10.1016/j.ijid.2019.08.007 10.1093/oncolo/oyad041 10.1038/nrdp.2017.9 10.1016/j.eururo.2018.05.002 10.1186/s13046-023-02848-1 10.1164/rccm.201309-1611OC 10.4081/oncol.2012.e18 10.1038/s41467-020-19408-2 10.1002/hep.23633 10.1007/s00705-011-1080-2 10.3201/eid2406.171612 10.1038/s41586-019-1906-8 10.1186/s12943-018-0814-0 10.1158/1078-0432.CCR-21-2972 10.3892/ol.2016.4989 10.1126/scitranslmed.aat7807 10.1038/s41467-022-29250-3 10.1093/cid/ciaa987 10.1136/jitc-2020-000705 10.1038/nrurol.2010.46 10.1016/j.vaccine.2015.09.066 10.1007/s12307-012-0111-1 10.1038/mt.2009.283 10.1007/s13365-019-00822-2 10.1111/tbed.13297 10.1158/2326-6066.CIR-19-0628 10.1128/jvi.01871-22 10.1056/NEJM200011023431804 10.1016/j.cell.2019.10.028 |
ContentType | Journal Article |
Copyright | 2024 The Authors. published by Wiley Periodicals LLC. 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. 2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2024 The Authors. published by Wiley Periodicals LLC. – notice: 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. – notice: 2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7TK 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 |
DOI | 10.1002/jmv.29568 |
DatabaseName | Wiley Open Access Journals Wiley Online Library Free Content Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Bacteriology Abstracts (Microbiology B) Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Genetics Abstracts Virology and AIDS Abstracts Technology Research Database Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Genetics Abstracts MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Open Access Journals url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1096-9071 |
EndPage | n/a |
ExternalDocumentID | 10_1002_jmv_29568 38549430 JMV29568 |
Genre | researchArticle Journal Article |
GrantInformation_xml | – fundername: China Postdoctoral Science Foundation – fundername: National Natural Science Foundation of China |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 31~ 33P 3O- 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS ECGQY EJD ELTNK EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E VH1 W8V W99 WBKPD WHG WIB WIH WIJ WIK WIN WJL WNSPC WOHZO WQJ WRC WUP WXI WXSBR WYISQ X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~KM ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7TK 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 |
ID | FETCH-LOGICAL-c3488-fbb417f1b9bfc278fdd636922243ac0b4010185afa58e89c72fb946688a73fc33 |
IEDL.DBID | DR2 |
ISSN | 0146-6615 |
IngestDate | Sat Aug 17 05:32:05 EDT 2024 Thu Oct 10 21:58:20 EDT 2024 Fri Aug 23 04:53:38 EDT 2024 Sun Oct 13 10:33:44 EDT 2024 Sat Aug 24 00:51:39 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | cancer therapy immune checkpoint inhibitors tumor microenvironment oncolytic virus |
Language | English |
License | Attribution-NonCommercial-NoDerivs 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3488-fbb417f1b9bfc278fdd636922243ac0b4010185afa58e89c72fb946688a73fc33 |
Notes | Mengxuan Gui, Chongxin Wu, Ruoyao Qi, and Yue Zeng contributed equally to this study. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-9591-634X 0000-0002-6286-5574 0000-0003-0179-5266 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.29568 |
PMID | 38549430 |
PQID | 3048359790 |
PQPubID | 105515 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_3022569027 proquest_journals_3048359790 crossref_primary_10_1002_jmv_29568 pubmed_primary_38549430 wiley_primary_10_1002_jmv_29568_JMV29568 |
PublicationCentury | 2000 |
PublicationDate | April 2024 2024-Apr 2024-04-00 20240401 |
PublicationDateYYYYMMDD | 2024-04-01 |
PublicationDate_xml | – month: 04 year: 2024 text: April 2024 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: London |
PublicationTitle | Journal of medical virology |
PublicationTitleAlternate | J Med Virol |
PublicationYear | 2024 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2023; 97 2017; 7 2021; 27 2015; 14 2017; 3 2011; 1 2018; 128 2010; 18 2015; 33 2016; 30 2021; 186 2022; 65 2020; 11 2007; 30 2021; 71 2011; 156 2022; 28 2016; 12 2014; 64 2018; 68 2018; 24 2020; 8 2023; 42 2009; 14 2018; 17 2023; 22 2023; 28 2020; 73 2019; 66 2019; 87 2017; 13 2022; 13 2020; 577 2009; 9 2020; 26 2019; 179 2018; 74 2000; 343 2012; 6 2018; 10 2012; 5 2010; 7 2010; 52 2008; 371 2014; 32 2014; 189 2012; 62 2016; 22 e_1_2_9_31_1 e_1_2_9_52_1 e_1_2_9_50_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_12_1 e_1_2_9_33_1 Wang H (e_1_2_9_43_1) 2021; 27 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_18_1 Fu X (e_1_2_9_41_1) 2007; 30 e_1_2_9_20_1 e_1_2_9_45_1 e_1_2_9_24_1 e_1_2_9_8_1 e_1_2_9_6_1 e_1_2_9_4_1 e_1_2_9_2_1 e_1_2_9_26_1 e_1_2_9_49_1 e_1_2_9_28_1 e_1_2_9_47_1 e_1_2_9_30_1 e_1_2_9_51_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_19_1 e_1_2_9_42_1 e_1_2_9_40_1 e_1_2_9_21_1 e_1_2_9_46_1 e_1_2_9_23_1 e_1_2_9_44_1 e_1_2_9_7_1 e_1_2_9_5_1 e_1_2_9_3_1 Lee JM (e_1_2_9_22_1) 2016; 30 e_1_2_9_9_1 e_1_2_9_25_1 e_1_2_9_27_1 e_1_2_9_48_1 e_1_2_9_29_1 |
References_xml | – volume: 32 start-page: 189 year: 2014 end-page: 225 article-title: Adoptive immunotherapy for cancer or viruses publication-title: Annu Rev Immunol – volume: 9 start-page: 785 issue: 6 year: 2009 end-page: 793 article-title: Targeting the met signaling pathway in renal cancer publication-title: Expert Rev Anticancer Ther – volume: 3 year: 2017 article-title: Renal cell carcinoma publication-title: Nat Rev Dis Primers – volume: 186 year: 2021 article-title: Adefovir dipivoxil efficiently inhibits the proliferation of pseudorabies virus in vitro and in vivo publication-title: Antiviral Res – volume: 14 start-page: 800 issue: 8 year: 2009 end-page: 805 article-title: Sorafenib and sunitinib publication-title: Oncologist – volume: 1 start-page: 222 issue: 3 year: 2011 end-page: 235 article-title: Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene publication-title: Cancer Discov – volume: 13 start-page: 1533 issue: 1 year: 2022 article-title: Structures of pseudorabies virus capsids publication-title: Nat Commun – volume: 10 issue: 422 year: 2018 article-title: Neoadjuvant oncolytic virotherapy before surgery sensitizes triple‐negative breast cancer to immune checkpoint therapy publication-title: Sci Transl Med – volume: 179 start-page: 1191 issue: 5 year: 2019 end-page: 1206.e1121 article-title: B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer publication-title: Cell – volume: 68 start-page: 394 issue: 6 year: 2018 end-page: 424 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin – volume: 22 start-page: 5839 issue: 23 year: 2016 end-page: 5850 article-title: Repurposing sunitinib with oncolytic reovirus as a novel immunotherapeutic strategy for renal cell carcinoma publication-title: Clin Cancer Res – volume: 66 start-page: 2562 issue: 6 year: 2019 end-page: 2565 article-title: Dynamic cerebrospinal fluid analyses of severe pseudorabies encephalitis publication-title: Transbound Emerg Dis – volume: 343 start-page: 1305 issue: 18 year: 2000 end-page: 1311 article-title: Obesity, hypertension, and the risk of kidney cancer in men publication-title: N Engl J Med – volume: 62 start-page: 309 issue: 5 year: 2012 end-page: 335 article-title: Immunotherapy of cancer in 2012 publication-title: CA Cancer J Clin – volume: 30 start-page: 67 issue: 1 year: 2016 end-page: 69 article-title: Challenges and opportunities for immunotherapies in gynecologic cancers publication-title: Oncology (Williston Park, N.Y.) – volume: 65 start-page: 1721 issue: 10 year: 2022 end-page: 1733 article-title: Glucose‐mediated insulin secretion is improved in FHL2‐deficient mice and elevated FHL2 expression in humans is associated with type 2 diabetes publication-title: Diabetologia – volume: 30 start-page: 1561 issue: 6 year: 2007 end-page: 1567 article-title: Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma publication-title: Int J Oncol – volume: 71 start-page: 209 issue: 3 year: 2021 end-page: 249 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin – volume: 14 start-page: 642 issue: 9 year: 2015 end-page: 662 article-title: Oncolytic viruses: a new class of immunotherapy drugs publication-title: Nat Rev Drug Discov – volume: 74 start-page: 611 issue: 5 year: 2018 end-page: 620 article-title: Adjuvant vascular endothelial growth factor‐targeted therapy in renal cell carcinoma: A systematic review and pooled analysis publication-title: Eur Urol – volume: 128 start-page: 1413 issue: 4 year: 2018 end-page: 1428 article-title: PD‐L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy publication-title: J Clin Invest – volume: 26 start-page: 442 year: 2020 end-page: 448 article-title: Human encephalitis caused by pseudorabies virus infection: a case report publication-title: J Neurovirol – volume: 5 start-page: 203 issue: 3 year: 2012 end-page: 209 article-title: Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma publication-title: Cancer Microenviron – volume: 73 start-page: e3690 issue: 11 year: 2020 end-page: e3700 article-title: A novel human acute encephalitis caused by pseudorabies virus variant strain publication-title: Clin Infect Dis – volume: 11 start-page: 5583 issue: 1 year: 2020 article-title: Integrated digital pathology and transcriptome analysis identifies molecular mediators of T‐cell exclusion in ovarian cancer publication-title: Nat Commun – volume: 33 start-page: 5733 issue: 43 year: 2015 end-page: 5740 article-title: Novel pseudorabies virus variant with defects in TK, gE and gI protects growing pigs against lethal challenge publication-title: Vaccine – volume: 22 start-page: 316 issue: 3 year: 2023 end-page: 330 article-title: Elevated THBS3 predicts poor overall survival for clear cell renal cell carcinoma and identifies LncRNA/RBP/THBS3 mRNA networks publication-title: Cell Cycle – volume: 8 start-page: 632 issue: 5 year: 2020 end-page: 647 article-title: Intratumoral delivery of a PD‐1‐Blocking scfv encoded in oncolytic HSV‐1 promotes antitumor immunity and synergizes with TIGIT blockade publication-title: Cancer Immunol Res – volume: 52 start-page: 360 issue: 1 year: 2010 end-page: 369 article-title: Sorafenib: where do we go from here? publication-title: Hepatology – volume: 13 issue: 5 year: 2017 article-title: Structural basis of nectin‐1 recognition by pseudorabies virus glycoprotein D publication-title: PLoS Pathog – volume: 577 start-page: 556 issue: 7791 year: 2020 end-page: 560 article-title: B cells are associated with survival and immunotherapy response in sarcoma publication-title: Nature – volume: 6 start-page: 18 issue: 2 year: 2012 article-title: Systemic adjuvant therapies in renal cell carcinoma publication-title: Oncol Rev – volume: 12 start-page: 2894 issue: 4 year: 2016 end-page: 2899 article-title: Eupatilin induces human renal cancer cell apoptosis via ROS‐mediated MAPK and PI3K/AKT signaling pathways publication-title: Oncol Lett – volume: 189 start-page: 832 issue: 7 year: 2014 end-page: 844 article-title: Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer publication-title: Am J Respir Crit Care Med – volume: 371 start-page: 569 issue: 9612 year: 2008 end-page: 578 article-title: Body‐mass index and incidence of cancer: a systematic review and meta‐analysis of prospective observational studies publication-title: Lancet – volume: 10 issue: 459 year: 2018 article-title: The hallmarks of successful anticancer immunotherapy publication-title: Sci Transl Med – volume: 42 start-page: 284 issue: 1 year: 2023 article-title: The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors publication-title: J Exp Clin Cancer Res: CR – volume: 18 start-page: 251 issue: 2 year: 2010 end-page: 263 article-title: Intelligent design: combination therapy with oncolytic viruses publication-title: Mol Ther – volume: 7 start-page: 107 year: 2017 article-title: Surgical management of advanced and metastatic renal cell carcinoma: a multidisciplinary approach publication-title: Front Oncol – volume: 97 issue: 2 year: 2023 article-title: Association of THBS3 with glycoprotein D promotes pseudorabies virus attachment, fusion, and entry publication-title: J Virol – volume: 10 issue: 471 year: 2018 article-title: MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation publication-title: Sci Transl Med – volume: 7 start-page: 245 issue: 5 year: 2010 end-page: 257 article-title: Epidemiology and risk factors for kidney cancer publication-title: Nat Rev Urol – volume: 17 start-page: 32 issue: 1 year: 2018 article-title: Engineering chimeric antigen receptor‐T cells for cancer treatment publication-title: Mol Cancer – volume: 87 start-page: 92 year: 2019 end-page: 99 article-title: Characteristics of human encephalitis caused by pseudorabies virus: a case series study publication-title: Int J Infect Dis – volume: 27 year: 2021 article-title: Bluetongue viruses act as novel oncolytic viruses to effectively inhibit human renal cancer cell growth in vitro and in vivo publication-title: Med Sci Monit – volume: 28 start-page: 664 issue: 8 year: 2023 end-page: 670 article-title: Regulatory issues: PMDA ‐ review of sakigake designation products: oncolytic virus therapy with delytact injection (Teserpaturev) for Malignant glioma publication-title: Oncologist – volume: 24 start-page: 1087 issue: 6 year: 2018 end-page: 1090 article-title: Human endophthalmitis caused by pseudorabies virus infection, China, 2017 publication-title: Emerging Infect Dis – volume: 8 issue: 2 year: 2020 article-title: SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery publication-title: J Immunother Cancer – volume: 156 start-page: 1691 issue: 10 year: 2011 end-page: 1705 article-title: Pseudorabies virus in wild swine: a global perspective publication-title: Arch Virol – volume: 28 start-page: 1540 issue: 8 year: 2022 end-page: 1548 article-title: Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open‐label phase I trial publication-title: Clin Cancer Res – volume: 64 start-page: 9 issue: 1 year: 2014 end-page: 29 article-title: Cancer statistics, 2014 publication-title: CA Cancer J Clin – ident: e_1_2_9_6_1 doi: 10.3322/caac.21208 – ident: e_1_2_9_7_1 doi: 10.3322/caac.21492 – ident: e_1_2_9_45_1 doi: 10.1080/15384101.2022.2117910 – ident: e_1_2_9_2_1 doi: 10.3322/caac.21660 – ident: e_1_2_9_46_1 doi: 10.1126/scitranslmed.aau0417 – ident: e_1_2_9_49_1 doi: 10.1126/scitranslmed.aao1641 – ident: e_1_2_9_18_1 doi: 10.3389/fonc.2017.00107 – ident: e_1_2_9_11_1 doi: 10.1016/S0140-6736(08)60269-X – ident: e_1_2_9_20_1 doi: 10.1634/theoncologist.2009-0088 – ident: e_1_2_9_39_1 doi: 10.1371/journal.ppat.1006314 – ident: e_1_2_9_25_1 doi: 10.1038/nrd4663 – ident: e_1_2_9_17_1 doi: 10.3322/caac.20132 – ident: e_1_2_9_42_1 doi: 10.1158/1078-0432.CCR-16-0143 – ident: e_1_2_9_9_1 doi: 10.1586/era.09.43 – ident: e_1_2_9_13_1 doi: 10.1007/s00125-022-05750-1 – ident: e_1_2_9_16_1 doi: 10.1146/annurev-immunol-032713-120136 – ident: e_1_2_9_48_1 doi: 10.1172/JCI98047 – ident: e_1_2_9_19_1 doi: 10.1158/2159-8290.CD-11-0098 – ident: e_1_2_9_31_1 doi: 10.1016/j.antiviral.2021.105014 – volume: 27 year: 2021 ident: e_1_2_9_43_1 article-title: Bluetongue viruses act as novel oncolytic viruses to effectively inhibit human renal cancer cell growth in vitro and in vivo publication-title: Med Sci Monit contributor: fullname: Wang H – ident: e_1_2_9_35_1 doi: 10.1016/j.ijid.2019.08.007 – ident: e_1_2_9_26_1 doi: 10.1093/oncolo/oyad041 – ident: e_1_2_9_3_1 doi: 10.1038/nrdp.2017.9 – ident: e_1_2_9_5_1 doi: 10.1016/j.eururo.2018.05.002 – ident: e_1_2_9_40_1 doi: 10.1186/s13046-023-02848-1 – ident: e_1_2_9_50_1 doi: 10.1164/rccm.201309-1611OC – ident: e_1_2_9_4_1 doi: 10.4081/oncol.2012.e18 – ident: e_1_2_9_28_1 doi: 10.1038/s41467-020-19408-2 – ident: e_1_2_9_21_1 doi: 10.1002/hep.23633 – ident: e_1_2_9_30_1 doi: 10.1007/s00705-011-1080-2 – ident: e_1_2_9_34_1 doi: 10.3201/eid2406.171612 – ident: e_1_2_9_52_1 doi: 10.1038/s41586-019-1906-8 – ident: e_1_2_9_29_1 doi: 10.1186/s12943-018-0814-0 – ident: e_1_2_9_8_1 doi: 10.1158/1078-0432.CCR-21-2972 – volume: 30 start-page: 1561 issue: 6 year: 2007 ident: e_1_2_9_41_1 article-title: Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma publication-title: Int J Oncol contributor: fullname: Fu X – ident: e_1_2_9_14_1 doi: 10.3892/ol.2016.4989 – ident: e_1_2_9_15_1 doi: 10.1126/scitranslmed.aat7807 – ident: e_1_2_9_32_1 doi: 10.1038/s41467-022-29250-3 – ident: e_1_2_9_36_1 doi: 10.1093/cid/ciaa987 – ident: e_1_2_9_24_1 doi: 10.1136/jitc-2020-000705 – ident: e_1_2_9_12_1 doi: 10.1038/nrurol.2010.46 – ident: e_1_2_9_33_1 doi: 10.1016/j.vaccine.2015.09.066 – ident: e_1_2_9_23_1 doi: 10.1007/s12307-012-0111-1 – ident: e_1_2_9_27_1 doi: 10.1038/mt.2009.283 – volume: 30 start-page: 67 issue: 1 year: 2016 ident: e_1_2_9_22_1 article-title: Challenges and opportunities for immunotherapies in gynecologic cancers publication-title: Oncology (Williston Park, N.Y.) contributor: fullname: Lee JM – ident: e_1_2_9_37_1 doi: 10.1007/s13365-019-00822-2 – ident: e_1_2_9_38_1 doi: 10.1111/tbed.13297 – ident: e_1_2_9_47_1 doi: 10.1158/2326-6066.CIR-19-0628 – ident: e_1_2_9_44_1 doi: 10.1128/jvi.01871-22 – ident: e_1_2_9_10_1 doi: 10.1056/NEJM200011023431804 – ident: e_1_2_9_51_1 doi: 10.1016/j.cell.2019.10.028 |
SSID | ssj0008922 |
Score | 2.4694324 |
Snippet | The global incidence rate of kidney cancer (KC) has been steadily increasing over the past 30 years. With the aging global population, kidney cancer has become... Abstract The global incidence rate of kidney cancer (KC) has been steadily increasing over the past 30 years. With the aging global population, kidney cancer... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | e29568 |
SubjectTerms | Animals Antibodies Anticancer properties Antitumor activity Cancer cancer therapy Cancer vaccines Cell activation Cell Line, Tumor Effectiveness Flow cytometry Herpesvirus 1, Suid - genetics Heterogeneity Humans immune checkpoint inhibitors Immunotherapy Kidney cancer Kidney Neoplasms Kidneys Lymphocytes Lymphocytes B Lymphocytes T Macrophages Metastases Mice Oncolysis oncolytic virus Oncolytic Viruses - genetics Programmed Cell Death 1 Receptor Pseudorabies Survival Swine Tumor Microenvironment Tumors Vaccines Vaccines, Attenuated Viruses |
Title | Swine pseudorabies virus attenuated vaccine reprograms the kidney cancer tumor microenvironment and synergizes with PD‐1 blockade |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.29568 https://www.ncbi.nlm.nih.gov/pubmed/38549430 https://www.proquest.com/docview/3048359790 https://search.proquest.com/docview/3022569027 |
Volume | 96 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS9xAFD6oD8UXe9HarVam4oMvWTczuUzok7QVEbZIq8WHQpgrbJfNymazok-F_oH-xv4Sz0k2a7UUik8J5Ewuc-4z53wB2BOpjyWPRCCl00GUJjZQaegDG1oZexQRY6k5uf8pOT6PTi7iiyV41_bCNPgQiwU30ozaXpOCK10e3IGGfh_Nupya3dD-EpAeBUSf76CjZNbsIKAlCNAHxS2qUI8fLEbe90V_BZj349Xa4Rw9hW_tqzZ1JsNuNdVdc_MAxfGR3_IM1uaBKDtsJOc5LLniBTzpz7fa1-Hnlys8ssvSVRbFRGNGzWaDSVUyQuQsKoxRLZspQ9SMoDHrOq-SYUDJhgNbuGtmSKImbFqNxhM2osq_P9rqmCosK6-p9XBwg_emBWF2-uH3j18h0-hhh8q6DTg_-nj2_jiY_7EhMAItQeC1jsLUhzrT3vBUemsTkSAnUBqU6emIEO1krLyKpZOZSbnXBHAvpUqFN0K8hJViXLhXwJLYJVwR1IzIIqutJNwry53hiUHatAO7Le_yywaYI28gmHmO05nX09mB7Zar-Vw3y1wQij7mUVmvA28Xl1GraKtEFW5cEQ3auSTDnL0Dm400LJ4iJObUkcDR-zVP__34_KT_tT55_f-kW7DKMW5qioO2YWU6qdwbjHumegeWeXS6U4v5LbZTAiE |
link.rule.ids | 315,786,790,1382,11589,27955,27956,46085,46327,46509,46751 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB6VIkEvvGkDBRbEgYvTeNePtdQLolShNBWCFvWCrH1KaRSniuOg9oTEH-A39pcwY8cpBSEhTrbkWT923rsznwFeitTHkkcikNLpIEoTG6g09IENrYw9ioix1Jw8OEj6R9HecXy8AtttL0yDD7FccCPNqO01KTgtSG9dooaejOddTt1u1-A6qntMarnz8RI8SmbNHgLaggC9UNziCvX41nLoVW_0R4h5NWKtXc7ubfjSvmxTaTLqVjPdNee_4Tj-79fcgVuLWJS9boTnLqy44h7cGCx22-_D909f8chOS1dZlBSNSTWbD6dVyQiUs6gwTLVsrgxRM0LHrEu9SoYxJRsNbeHOmCGhmrJZNZ5M2ZiK_37prGOqsKw8o-7D4Tnem9aE2Yedi28_QqbRyY6UdQ_gaPft4Zt-sPhpQ2AEGoPAax2FqQ91pr3hqfTWJiJBVqBAKNPTEYHayVh5FUsnM5NyrwnjXkqVCm-EeAirxaRwG8CS2CVcEdqMyCKrrSToK8ud4YlB2rQDL1rm5acNNkfeoDDzHKczr6ezA5stW_OFepa5ICB9TKWyXgeeLy-jYtFuiSrcpCIaNHVJhml7B9YbcVg-RUhMqyOBo1_VTP374_O9wef65NG_kz6Dm_3DwX6-_-7g_WNY4xhGNbVCm7A6m1buCYZBM_20lvafuf8Fag |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEB6VIlVcUHk2UGBBHLiYxrtre62eECUqhVSRoKg3a59SqOJEcZyqnJD6B_ob-0uYsRNDhZA42ZLHXmm_nZlvH_MZ4LXIQqK4FJFS3kQyS12kszhELnYqCThErKPi5OFxengij06T0w3YX9fCtPoQ3YIbeUYTr8nBZy7s_RYN_T5ZvuVU7HYLbssUmQPJOstRF4ZV3m4hYCiIMAkla1mhPt_rXr2ZjP5imDcJa5NxBttwd0UV2bsW23uw4cv7sDVcbYY_gMsv53hls8rXDoE0OOdly_G8rhhpZpY1skjHltqSNSPxyuYkVsWQ8rGzsSv9BbOE-Zwt6sl0ziZ0Nu-PwjemS8eqCyoOHP_Ab9OSLRsdXP-8ipnBHHimnX8IJ4MPX98fRqt_KkRWoK9GwRgZZyE2uQmWZyo4l4oUuwrx0rZvJGnOqUQHnSivcpvxYEiCXimdiWCFeASb5bT0O8DSxKdckxiMyKUzTpEylePe8tSibdaDV-vOLWatdEbRiiTzAhEoGgR6sLvu9mLlPVUhSOceZzp5vwcvu8c47mkzQ5d-WpMNRiKc2nNs53ELV9eKUDjrlQLfftPg9-_mi6Pht-bmyf-bvoCt0cGg-Pzx-NNTuMOR5LQneXZhczGv_TMkKQvzvBmMvwCECuO1 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Swine+pseudorabies+virus+attenuated+vaccine+reprograms+the+kidney+cancer+tumor+microenvironment+and+synergizes+with+PD%E2%80%901+blockade&rft.jtitle=Journal+of+medical+virology&rft.au=Gui%2C+Mengxuan&rft.au=Wu%2C+Chongxin&rft.au=Qi%2C+Ruoyao&rft.au=Zeng%2C+Yue&rft.date=2024-04-01&rft.issn=0146-6615&rft.eissn=1096-9071&rft.volume=96&rft.issue=4&rft.epage=n%2Fa&rft_id=info:doi/10.1002%2Fjmv.29568&rft.externalDBID=10.1002%252Fjmv.29568&rft.externalDocID=JMV29568 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon |